TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)

Trial Profile

TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs PSMA 617 (Primary) ; Cabazitaxel
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TheraP
  • Most Recent Events

    • 30 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 29 Nov 2017 Status changed from planning to not yet recruiting.
    • 10 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top